Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Recce Pharmaceuticals Ltd (Company) ACN 124 849 065 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Alan W Dunton Date of last notice 11 December 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Interest Nature of indirect interest (including registered holder) Danerius, LLC Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 22 February 2021 No. of securities held prior to change 70,000 Fully Paid Ordinary Shares Class Unlisted Options Number acquired 1,125,000 Unlisted Options, each exercisable at $1.56, expiring 22 February 2026 Number disposed N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nil cash consideration. Issue of Unlisted Options as approved by shareholders at the Annual General Meeting held on 30 November 2020. Further details on the issue can be found in the Notice of Meeting released to ASX on 30 October 2020. 70,000 Fully Paid Ordinary Shares 1,125,000 Unlisted Options Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of Unlisted Options as approved by shareholders at the Annual General Meeting held on 30 November 2020 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? No N/A N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011